Residency · Residency · Respirology

Bronchiectasis - Etiology and Management

Definition and Pathophysiology

Definition

Bronchiectasis is defined as the permanent, abnormal dilation of bronchi resulting from destruction of the elastic and muscular components of the bronchial wall. The diagnosis is established radiologically on high-resolution CT, where the characteristic findings include a broncho-arterial ratio exceeding 1.0 (the signet ring sign, in which the dilated bronchus appears larger than its accompanying pulmonary artery), lack of normal bronchial tapering toward the periphery, and visualization of bronchi within 1 cm of the pleural surface, a region where normal bronchi are too small to be resolved on CT imaging.

Cole's Vicious Cycle Hypothesis

The pathogenesis of bronchiectasis is best understood through Cole's vicious cycle hypothesis, which describes a self-perpetuating loop of airway damage. The cycle begins with impaired mucociliary clearance, whether from a primary defect (as in cystic fibrosis or primary ciliary dyskinesia) or secondary to airway injury. This impaired clearance leads to microbial colonization, which triggers a chronic inflammatory response dominated by neutrophils. Neutrophilic inflammation releases destructive enzymes, including neutrophil elastase and matrix metalloproteinases (MMP-8, MMP-9), along with reactive oxygen species, which cause progressive airway damage, further impairing clearance and perpetuating the cycle. This framework underscores the rationale for the multimodal treatment approach: interrupting the cycle at multiple points through airway clearance techniques, antimicrobial therapy, and anti-inflammatory interventions.

Morphologic Subtypes (Reid Classification)

The Reid classification categorizes bronchiectasis into three morphologic subtypes of increasing severity. Cylindrical bronchiectasis, the most common and mildest form, features uniform dilation of the bronchi with relatively preserved structural integrity. Varicose bronchiectasis demonstrates an irregular, beaded appearance with alternating areas of dilation and constriction, resembling varicose veins. Cystic or saccular bronchiectasis, the most severe form, is characterized by clusters of cysts at the terminal bronchi and is associated with advanced, destructive disease.

Etiology - Systematic Approach

Post-Infectious (Most Common Globally)

Post-infectious bronchiectasis remains the most common etiology worldwide. Prior severe pneumonia, particularly during childhood, along with measles, pertussis, and tuberculosis, can leave permanent structural airway damage that evolves into bronchiectasis over years to decades. Non-tuberculous mycobacteria (NTM) represent a unique challenge, as they can function as both a cause and a consequence of bronchiectasis, creating a bidirectional relationship. Allergic bronchopulmonary aspergillosis (ABPA) characteristically produces central bronchiectasis and is identified by elevated total IgE, Aspergillus-specific IgE and IgG, and peripheral eosinophilia.

Immune Deficiency

Immunodeficiency represents an important and treatable cause of bronchiectasis. Common variable immunodeficiency (CVID), characterized by low IgG, IgA, and/or IgM with poor responses to vaccination, is the most common primary immunodeficiency causing bronchiectasis and warrants immunoglobulin replacement therapy. Specific antibody deficiency presents with normal total immunoglobulin levels but an inability to mount adequate responses to polysaccharide vaccines, identified through prevaccination and postvaccination antibody titers. IgA deficiency, though the most common primary immunodeficiency at a prevalence of 1 in 500, is usually asymptomatic; in symptomatic cases, IgG subclass measurement is appropriate. Secondary immunodeficiency from HIV, chronic lymphocytic leukemia, multiple myeloma, or post-transplant immunosuppression should also be considered.

Genetic/Congenital

Cystic fibrosis is the most common genetic cause of bronchiectasis, and CFTR mutation testing is mandatory in cases of young-onset or idiopathic bronchiectasis. Primary ciliary dyskinesia (PCD), an autosomal recessive condition, should be suspected when bronchiectasis is accompanied by situs inversus (present in approximately 50% of cases, constituting Kartagener syndrome), chronic sinusitis, or recurrent otitis media. Screening begins with nasal nitric oxide measurement (values below 77 nL/min are suggestive), with confirmation through electron microscopy of ciliary ultrastructure or genetic testing. Alpha-1 antitrypsin deficiency can cause bronchiectasis independently of emphysema.

Autoimmune/Inflammatory

Among connective tissue diseases, rheumatoid arthritis is the most common cause of bronchiectasis, and the airway disease may precede articular symptoms. Inflammatory bowel disease, particularly ulcerative colitis, is associated with bronchiectasis through mechanisms that remain incompletely understood. ANCA-associated vasculitis, particularly granulomatosis with polyangiitis, can cause destructive airway disease with resultant bronchiectasis.

Other

Additional etiologies include chronic aspiration (necessitating evaluation of swallowing function), yellow nail syndrome (a rare triad of yellow nails, lymphedema, and pleural effusions with bronchiectasis), Mounier-Kuhn syndrome (tracheobronchomegaly), and Williams-Campbell syndrome (congenital deficiency of bronchial cartilage). Despite thorough evaluation, 30-50% of cases remain idiopathic.

Etiologic Categories

Minimum Etiologic Workup (ERS 2017 Guidelines)

The ERS 2017 guidelines recommend a minimum etiologic workup for all newly diagnosed bronchiectasis patients, including CBC with differential, quantitative immunoglobulins (IgG, IgA, IgM), total IgE, Aspergillus-specific IgE and IgG, CFTR mutation testing (if under age 40 or clinical suspicion exists), and sputum culture including mycobacterial cultures. Additional testing based on clinical context may include specific antibody responses to pneumococcal polysaccharide vaccine, alpha-1 antitrypsin level, nasal nitric oxide or PCD genetic testing, and autoimmune serologies.

<image>A diagnostic workup algorithm for bronchiectasis etiology. Start with confirmed bronchiectasis on HRCT. Show first-line investigations as a panel: CBC, immunoglobulins, IgE, Aspergillus serology, sputum culture with AFB, CFTR testing. Based on results, branch into secondary testing: if immunoglobulin abnormality then vaccine responses and hematology referral; if elevated IgE/Aspergillus positive then ABPA workup (Rosenberg-Patterson criteria); if situs inversus or recurrent sinusitis then PCD testing; if young onset then CF sweat test and genetic testing. Show final classification categories: post-infectious, immunodeficiency, ABPA, CF, PCD, autoimmune, idiopathic. Include prevalence percentages for each category. Use a clean flowchart format with color-coded pathways.</image>

Clinical Assessment and Monitoring

Severity Scoring

Two validated severity scoring systems guide clinical management and prognostication. The Bronchiectasis Severity Index (BSI) incorporates age, BMI, FEV1 percent predicted, hospital admissions, exacerbation frequency, MRC dyspnea score, Pseudomonas colonization, number of lobes affected, and radiologic severity. Scores classify patients as mild (0-4), moderate (5-8), or severe (9 or greater), with the BSI predicting mortality, exacerbation frequency, and quality of life. The FACED score offers a simpler alternative using FEV1, age, colonization with Pseudomonas, extension (number of lobes), and dyspnea, though it is less discriminative than the BSI.

Sputum Microbiology

Regular sputum surveillance is fundamental to bronchiectasis management. Routine cultures should be obtained at initial assessment and during each exacerbation. Haemophilus influenzae is the most commonly isolated pathogen overall. Pseudomonas aeruginosa colonization carries particular clinical significance, as it is independently associated with a doubled rate of FEV1 decline, more frequent exacerbations, and increased mortality. NTM screening, with Mycobacterium avium complex (MAC) being the most commonly identified species, should be performed in all bronchiectasis patients at baseline.

Monitoring

Longitudinal monitoring should include annual spirometry, as the mean FEV1 decline in bronchiectasis averages 50-55 mL per year compared to 25-30 mL per year in healthy adults. Sputum cultures should be obtained every 6-12 months and during exacerbations. Annual review of exacerbation frequency, sputum volume, and quality of life using validated instruments such as the QoL-B questionnaire provides a comprehensive assessment of disease trajectory.

Management - Stable Disease

Airway Clearance Techniques (ACT)

Airway clearance techniques represent the cornerstone of bronchiectasis management and should be prescribed to all patients with productive cough. The active cycle of breathing technique (ACBT) combines breathing control with thoracic expansion exercises and the forced expiratory technique (huffing). Oscillating positive expiratory pressure (PEP) devices, including the Aerobika, Flutter, and Acapella, provide vibration and positive pressure to mobilize secretions. Postural drainage uses gravity-assisted positioning. High-frequency chest wall oscillation (vest therapy) offers an alternative for patients unable to perform other techniques. Hypertonic saline nebulization at 6-7% concentration improves mucociliary clearance but requires a tolerance test given the risk of bronchospasm, with pre-treatment bronchodilator administration.

Pharmacotherapy - Maintenance

Mucoactive agents play an important supportive role. Hypertonic saline at 6-7% nebulized twice daily enhances mucociliary clearance. Critically, dornase alfa (rhDNase), while beneficial in cystic fibrosis, is contraindicated in non-CF bronchiectasis, where it was shown to worsen outcomes in a randomized trial. Long-term macrolide therapy with azithromycin (250 mg daily or 500 mg three times weekly) has been consistently demonstrated to reduce exacerbations by 30-50% across the BAT, EMBRACE, and BLESS trials. ERS 2017 guidelines recommend macrolide therapy for patients with 3 or more exacerbations per year, with the critical prerequisite of screening for NTM before initiation to avoid the development of macrolide resistance in unrecognized NTM infection. Baseline ECG (for QTc assessment) and monitoring of hearing and liver function are also required. Inhaled antibiotics, including tobramycin 300 mg nebulized twice daily (28 days on, 28 days off), colistin, and ciprofloxacin dry powder inhaler, are reserved for Pseudomonas-colonized patients with 3 or more exacerbations per year despite oral macrolides and ACT. Bronchodilators lack strong trial evidence specific to bronchiectasis but are indicated when concurrent airflow obstruction or COPD-bronchiectasis overlap is present. ICS are not routinely recommended unless coexistent asthma or COPD is present, as they carry the risk of increasing infection burden.

Pseudomonas Eradication

ERS 2017 guidelines recommend attempting eradication on first isolation of Pseudomonas. The standard regimen consists of ciprofloxacin 750 mg orally twice daily for 2 weeks, followed by inhaled tobramycin or colistin for 3 months. Eradication is successful in approximately 50-60% of cases and, when sustained, is associated with improved clinical outcomes. Confirmation of eradication requires monthly sputum cultures for 3 consecutive months.

<image>A comprehensive management pyramid for bronchiectasis, structured in tiers from base to apex. Base tier (all patients): airway clearance techniques, treat underlying etiology, vaccinations, smoking cessation, exercise/pulmonary rehabilitation. Second tier (symptomatic/productive cough): mucoactive therapy (hypertonic saline), bronchodilators if airflow obstruction. Third tier (>= 3 exacerbations/year): long-term macrolide therapy (azithromycin). Fourth tier (Pseudomonas colonized with recurrent exacerbations despite macrolide): inhaled antibiotics (tobramycin, colistin). Apex (refractory): surgery (lobectomy for localized disease), lung transplant referral. On the side, show monitoring schedule: sputum culture q6-12 months, annual spirometry, BSI scoring.</image>

Exacerbation Management

Definition

A bronchiectasis exacerbation is defined as an increase in sputum volume or purulence, and/or worsening dyspnea, cough, or constitutional symptoms that requires antibiotic treatment. Patients typically experience 1.5-3 exacerbations per year, and those classified as frequent exacerbators (3 or more per year) have a demonstrably worse prognosis with accelerated decline.

Antibiotic Selection

Empiric antibiotic therapy should be guided by prior sputum culture results, targeting the known colonizing organism whenever possible. For patients without prior Pseudomonas isolation, amoxicillin-clavulanate 875/125 mg twice daily or doxycycline 100 mg twice daily for 14 days is appropriate. For Pseudomonas-colonized patients, ciprofloxacin 750 mg orally twice daily for 14 days is the first-line oral option; intravenous options including piperacillin-tazobactam, ceftazidime, or meropenem are reserved for severe exacerbations or oral-resistant organisms. The standard treatment duration in bronchiectasis is 14 days, longer than for typical pneumonia, reflecting the impaired airway clearance mechanisms. Sputum culture should be obtained before starting antibiotics whenever feasible.

ABPA-Specific Management

ABPA diagnosis follows the Agarwal criteria, requiring asthma or CF plus elevated total IgE (usually above 1000 IU/mL), positive Aspergillus skin test or elevated Aspergillus-specific IgE, elevated Aspergillus-specific IgG, radiographic infiltrates or central bronchiectasis, and blood eosinophilia. Treatment consists of prednisolone 0.5 mg/kg for 2 weeks followed by a taper over 3-5 months, with itraconazole 200 mg twice daily for 16 weeks as a steroid-sparing agent. Total IgE should be monitored every 6-8 weeks, with relapse suspected if IgE doubles from its nadir value. Omalizumab (anti-IgE) has shown promise as a steroid-sparing agent in case series.

Surgical Considerations

Lobectomy or segmentectomy is considered for localized bronchiectasis refractory to medical therapy, particularly in patients with recurrent infections or hemoptysis from single-lobe disease, where outcomes are best. Bronchial artery embolization is the intervention of choice for massive hemoptysis (greater than 300 mL per 24 hours or hemodynamically significant bleeding). Lung transplantation should be considered in patients with diffuse disease showing progressive decline, FEV1 below 30%, frequent hospitalizations, or respiratory failure.

Key Clinical Pearls

• Dornase alfa (rhDNase/Pulmozyme) improves outcomes in CF bronchiectasis but is HARMFUL in non-CF bronchiectasis and should never be prescribed for non-CF patients
• Pseudomonas colonization is an independent predictor of morbidity and mortality; attempt eradication on first isolation with ciprofloxacin + inhaled antibiotics
• Long-term azithromycin is the most evidence-based preventive therapy for exacerbation reduction in bronchiectasis (>= 3 exacerbations/year); always exclude NTM before starting
• Up to 50% of bronchiectasis cases remain idiopathic after thorough evaluation; a systematic etiologic workup should still be performed in all patients
• Exacerbation treatment duration in bronchiectasis is 14 days, longer than standard respiratory infection treatment

References

1. Polverino E, Goeminne PC, McDonnell MJ, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J. 2017;50(3):1700629.
2. Chalmers JD, Aliberti S, Filonenko A, et al. Characterization of the "Frequent Exacerbator Phenotype" in Bronchiectasis. Am J Respir Crit Care Med. 2018;197(11):1410-1420.
3. Wong C, Jayaram L, Karalus N, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):660-667.
4. O'Donnell AE. Bronchiectasis - A Clinical Review. N Engl J Med. 2022;387(6):533-545.
5. Chalmers JD, Goeminne P, Aliberti S, et al. The Bronchiectasis Severity Index: An International Derivation and Validation Study. Am J Respir Crit Care Med. 2014;189(5):576-585.

Read this lecture as Markdown